NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Rheumatoid Arthritis

Interventions: Tocilizumab

Countries: Hungary

The aim of this non-interventional study in Hungarian participants is to gather real life data about the efficacy and safety of tocilizumab SC monotherapy in RA, to assess data about pattern of usage of tocilizumab monotherapy in RA disease management.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria
* Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label
* Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors where continued methotrexate treatment was deemed inappropriate

Exclusion Criteria:

* Treatment with tocilizumab more than 8 weeks prior to enrollment
* Failure to meet local tocilizumab label indication criteria
* Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy
* Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy
* History of any other autoimmune or joint inflammatory disease

Locations (18)

Budapest, Hungary
Budapest, Hungary
Budapest, Hungary
Debrecen, Hungary
Eger, Hungary
Esztergom, Hungary
Győr, Hungary
Gyula, Hungary
Hévíz, Hungary
Kecskemét, Hungary
Kistarcsa, Hungary
Miskolc, Hungary
Nyíregyháza, Hungary
Pécs, Hungary
Szeged, Hungary
Székesfehérvár, Hungary
Szombathely, Hungary
Veszprém, Hungary